for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biogen Inc

BIIB.O

Latest Trade

275.84USD

Change

-4.45(-1.59%)

Volume

1,539,004

Today's Range

275.43

 - 

282.60

52 Week Range

223.25

 - 

374.99

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
280.29
Open
280.00
Volume
1,539,004
3M AVG Volume
35.88
Today's High
282.60
Today's Low
275.43
52 Week High
374.99
52 Week Low
223.25
Shares Out (MIL)
153.88
Market Cap (MIL)
41,035.61
Forward P/E
7.99
Dividend (Yield %)
--

Next Event

Q4 2020 Biogen Inc Earnings Release

Latest Developments

More

Biogen Reports 10.7% Passive Stake In Sage Therapeutics

Biogen To Launch Study To Develop Digital Biomarkers Of Cognitive Health Using Apple Watch And iPhone

Biogen Says Files New Drug Application For Aducanumab In Japan

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Industry

Biotechnology & Drugs

Contact Info

225 Binney St

CAMBRIDGE, MA

02142-1031

United States

+1.781.4642000

https://www.biogen.com/

Executive Leadership

Stelios B. Papadopoulos

Independent Chairman of the Board

Michel Vounatsos

Chief Executive Officer, Director

Michael R. McDonnell

Chief Financial Officer, Executive Vice President

Ginger Gregory

Chief Human Resource Officer, Executive Vice President

Susan H. Alexander

Executive Vice President, Chief Legal Officer and Secretary

Key Stats

2.67 mean rating - 33 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

12.3K

2018

13.5K

2019

14.4K

2020(E)

13.4K
EPS (USD)

2017

21.810

2018

26.200

2019

33.570

2020(E)

33.388
Price To Earnings (TTM)
8.83
Price To Sales (TTM)
2.88
Price To Book (MRQ)
3.81
Price To Cash Flow (TTM)
7.27
Total Debt To Equity (MRQ)
69.02
LT Debt To Equity (MRQ)
69.02
Return on Investment (TTM)
23.39
Return on Equity (TTM)
19.72

Latest News

Latest News

Biogen to pay $22 million to resolve U.S. drug charity kickback probe

Biogen Inc has agreed to pay $22 million to resolve U.S. allegations that it illegally used two charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay them kickbacks to use its multiple sclerosis drugs.

Biogen to pay $22 million to resolve U.S. drug charity kickback probe

Biogen Inc has agreed to pay $22 million to resolve U.S. allegations that it illegally used two charities that help cover Medicare patients' out-of-pocket drug costs as a means to pay them kickbacks to use its multiple sclerosis drugs.

Biogen files for Japan approval for Alzheimer's drug developed with Eisai

Biogen said on Thursday it filed for regulatory approval in Japan for an Alzheimer's disease drug it developed with local partner Eisai Co.

Biogen bets on depression drug in $1.5 billion deal with Sage Therapeutics

Biogen Inc will take a $650 million stake in Sage Therapeutics and make an upfront payment of $875 million to jointly develop and sell treatments for depression and other neurological disorders, the two companies said on Friday.

Biogen, Sage Therapeutics enter $1.5 bln deal to develop, sell depression drug

Biogen Inc has entered into an agreement with Sage Therapeutics to jointly develop and sell a treatment for major depressive disorder, the two companies said on Friday.

Merck KGaA lifts earnings guidance on demand for lab tools

Healthcare and chemicals group Merck KGaA <MRCG.DE> lifted its guidance for full year earnings after the scramble to ready treatments and vaccines against the coronavirus bolstered demand for its supplies for biotech labs.

Biogen plunges 30% after FDA panel votes against Alzheimer's drug

Biogen Inc's <BIIB.O> shares slumped about 30% on Monday as the drugmaker's chances of getting a regulatory approval for its experiment Alzheimer's treatment suffered a blow after a panel of experts to the U.S. Food and Drug Administration voted against the medicine.

Combative U.S. FDA panel votes against Biogen Alzheimer's drug

A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted that a potential Alzheimer’s treatment from Biogen Inc has not been proven to slow progression of the disease, a sharp rebuke to agency staff who earlier this week praised the drug.

UPDATE 1-U.S. FDA panel votes successful study on Biogen Alzheimer's drug cannot stand alone

A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted that one of two large studies on Biogen Inc's experimental Alzheimer's disease drug cannot be viewed alone without regard for the other failed trial.

FDA advisory panel convenes to discuss whether Biogen Alzheimer's drug should be approved

A meeting of outside advisers to the U.S. Food and Drug Administration convened on Friday to discuss whether to recommend approval of Biogen Inc's experimental Alzheimer's disease drug aducanumab.

Biogen Alzheimer's drug closer to approval with U.S. FDA staff backing, shares jump 40%

Biogen Inc has shown "exceptionally persuasive" evidence that its experimental Alzheimer's disease drug is effective, U.S. Food and Drug Administration staff said on Wednesday, elevating its chances of a swift approval and sending company shares soaring.

BRIEF-FDA Staff Says Biogen Has Provided Substantial Evidence Of Effectiveness On Alzheimer’s Drug

* U.S. FDA STAFF SAYS BIOGEN INC HAS PROVIDED SUBSTANTIAL EVIDENCE OF EFFECTIVENESS TO SUPPORT APPROVAL OF ALZHEIMER’S DRUG: DOCUMENTS Source: (https://bit.ly/3exlbFx) Further company coverage:

U.S. experts to review Biogen drug that could be first new Alzheimer's treatment in decades

U.S. health experts this week will decide whether to recommend approval for Biogen Inc's <BIIB.O> Alzheimer's drug, which could become the first new treatment for the mind-wasting disease in decades even as serious questions persist over whether data show if it works.

FDA bars critic from review panel of Biogen's controversial Alzheimer's drug

The U.S. Food and Drug Administration, citing conflict of interest, has recused a member of an 11-person advisory committee set to review Biogen Inc's experimental Alzheimer's drug aducanumab on Friday.

UPDATE 1-EMA to review Biogen's aducanumab drug for Alzheimer's

Biogen Inc and Eisai Co Ltd said on Friday the European health regulator has accepted for review the marketing application for their closely watched experimental Alzheimer's treatment aducanumab.

EMA accepts Biogen's Alzheimer's treatment aducanumab for review

Biogen Inc and partner Eisai Co Ltd said on Friday the European health regulator has accepted for review the marketing application for its closely-watched experimental Alzheimer's treatment aducanumab.

Biogen readies for U.S. launch of Alzheimer's drug ahead of FDA meeting

Biogen Inc <BIIB.O> said on Wednesday it was diverting part of its budget and resources for blockbuster multiple sclerosis drug Tecfidera towards a potential launch of its Alzheimer's disease drug, aducanumab.

BRIEF-Biogen Says U.S. FDA Decision On Aducanumab Would Influnce Other Regulators: Conf. Call

* BIOGEN INC CEO SAYS UPCOMING FDA PANEL MEETING FOR ADUCANUMAB IS CO'S HIGHEST PRIORITY: CONF. CALL

Biogen, gene-editing startup Scribe to develop therapies for Lou Gehrig's disease

U.S. drugmaker Biogen Inc and gene-editing startup Scribe Therapeutics Inc will jointly develop therapies for treating underlying genetic causes of amyotrophic lateral sclerosis (ALS), a fatal neurological disorder better known as Lou Gehrig's disease.

Merck, Pfizer prevail in patent fight with Biogen over multiple sclerosis drug

Note: This story has been corrected to name Merck KGaA, not Merck & Co, in the first paragraph.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up